The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
This real-world study showed that nearly 17% of patients continued SZC therapy for ≥90 days. Long-term therapy was associated with lower RAASi discontinuation and reduced healthcare costs due to hospitalizations and outpatient specialist services, suggesting that SZC can potentially provide clinical and economic benefits for HK management.
Authors
- Anna Rita Maurizi
- Marco Gnesi (ORCID: https://orcid.org/0000-0001-6022-6325)
- Nicola Cosentino (ORCID: https://orcid.org/0000-0002-8628-3106)
- Francesca Daniel
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- V. Mongelli (ORCID: https://orcid.org/0000-0001-6022-6325)
- Melania Leogrande (ORCID: https://orcid.org/0009-0004-2092-4638)
- Marta Nugnes (ORCID: https://orcid.org/0009-0003-7777-7862)
- Andrea Merlo (ORCID: https://orcid.org/0000-0002-7219-9624)
Institutions
- AstraZeneca (France) (FR)
- AstraZeneca (Brazil) (BR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1080/13696998.2025.2487357
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00